SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as investors engage in high-risk, speculative activity characterized by intense volatility and rapid price swings common in meme coin cycles. The community is actively debating the project's long-term sustainability while others discuss potential entry points and strategies for navigating what many characterize as a high-stakes pump and dump cycle.

Spdr Dow Jones Industrial Average ETF Trust - Units of undivided interest in DIAMONDS Trust Series 1

The DIA is currently caught in intense volatility as traders debate the legitimacy of contradictory reports regarding U.S.-Iran negotiations, with community sentiment deeply polarized between optimism for a de-escalation deal and skepticism over perceived market manipulation. Investors remain highly sensitive to geopolitical headlines, as the community actively discusses the risk of a potential ground invasion versus a short-term relief rally.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy is capturing significant attention following its recent Nasdaq listing, driven by high-stakes speculation surrounding its exploration rights for a vast oil basin in the Jameson Land region. While the community is actively debating the company's long-term potential and the credibility of its leadership, many traders are closely monitoring price volatility and volume as they weigh the speculative nature of these Arctic drilling plans.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is trending following its recent Nasdaq debut via a SPAC merger, sparking intense community debate regarding stock availability, alleged broker settlement delays, and concerns over potential market manipulation. Investors are actively discussing the firm's photonic quantum computing prospects alongside technical speculation about float dynamics and potential short-term volatility.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is currently a focal point for crypto traders as the community debates its long-term potential against a backdrop of technical volatility and upcoming regulatory developments like the Clarity Act. While some investors are accumulating aggressively, citing supply dynamics and potential institutional interest as catalysts for a breakout, others remain skeptical, pointing to the asset's recent underperformance and lack of ETF inflows.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is capturing significant trader attention as part of a speculative rotation into aquatic-themed meme coins following recent movements in similar tokens. The community is actively debating the potential for quick gains, with proponents pushing the narrative of low market capitalization while skeptics warn of volatility and typical meme coin risks.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently generating significant controversy as investors debate whether it is a legitimate Layer-1 blockchain project or a sophisticated scam, with many citing frustration over delayed token claims, locked wallets, and confusing market data. While some community members remain optimistic about long-term potential and mining rewards, others are actively warning of a "rug pull" due to widespread technical issues and concerns over the authenticity of its trading venues.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is experiencing heightened volatility and intense social media discourse as investors debate its long-term potential against a backdrop of macroeconomic uncertainty and sector-wide sentiment shifts. The community remains sharply divided, with bulls aggressively citing strong earnings momentum and data-moat advantages as a reason to buy the dip, while bears express concern over macro pressures and the stock's tendency to trade as a high-beta asset.

Investment Managers Series Trust II - Alternative Access First Priority CLO Bond ETF

Listed Funds Trust - AAF First Priority CLO Bond ETF

Investors are actively discussing $AAA as a potential cash alternative, with many participants highlighting its performance during ex-dividend dates. The conversation frequently features technical testing and broader market commentary as users evaluate the fund's role within their portfolios.

The Shrimp Army

SHRIMPS is trending as part of a broader wave of speculative ocean-themed meme coins that the community is actively trading for quick momentum gains. Participants are intensely focused on rapid volatility and the potential for these micro-cap tokens to drop zeros, though many caution others about the high risk of rug pulls and the necessity of taking profits early.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Biotech, and Defense Converge: Small Caps Chase Big Markets as Innovation Narrative Heats Up

Today's top stocks include $LNAI, $HCTI, $TGNT, $KOD, $NAVN, $BTBD

Lunai Bioworks Unveils AI-Driven National Consortium to Fast-Track Chemical Defense Countermeasures

Lunai Bioworks (NASDAQ:LNAI) launched a new national consortium aimed at transforming how the United States develops medical countermeasures against emerging chemical threats. Operating through its subsidiary BioSymetrics, the company introduced the Pathfinder Consortium, an academic-industry alliance designed to unify historically fragmented chemical defense efforts across government, academia, and biotech into a single, execution-focused platform.

<ul class="summary-bullets"><li>The deal would expand Lunai’s capacity to develop treatments for neurological disorders.</li><li>The transaction is executed through Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share.</li><li>The acquired technology enables compounds to remain inactive in the body until they reach the brain, where they are selectively activated.</li></ul>Lunai Bioworks, Inc. (LNAI) announced a $20 million acquisition to advance its central nervous system (CNS) drug development.&nbsp;The company will acquire blood-brain barrier (BBB) delivery technology and Alzheimer's therapeutic assets for $20 million from the Clemann Group, SAS, or its assignee, marking an expansion of Lunai’s capabilities in neurological drug research.<h2 class="st-heading-2">Transforming CNS Drug Delivery</h2>The transaction is structured as Series B Convertible Preferred shares at a fixed conversion price of $1.5 per share, with a cap on beneficial ownership at 19.9% to remain compliant with Nasdaq regulations.&nbsp;The newly acquired delivery platform addresses one of the most persistent challenges in central nervous system (CNS) drug development, which is the effective transport of therapeutics across the blood-brain barrier.The technology ensures that compounds remain inactive in the body until reaching the brain, where they activate to target specific neurological pathways.&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks stock</a> traded over 25% higher on Thursday morning. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;<h2 class="st-heading-2">Strengthening Lunai’s Alzheimer’s Pipeline</h2>This acquisition directly strengthens Lunai’s Alzheimer’s program by combining validated target identification with a strong delivery method. The platform enables advanced treatments for CNS disorders where conventional drugs face penetration limitations, potentially improving both safety and effectiveness.&nbsp;<blockquote>&nbsp;"We are now combining the ability to identify the right biology with a validated mechanism to deliver therapies directly into the brain.”— David Weinstein, CEO, Lunai Bioworks</blockquote>On March 19, Lunai launched the Pathfinder Consortium, a national academic-industry alliance to accelerate the development of chemical countermeasures for battlefield and terrorism threats.&nbsp;LNAI stock has declined by over 35% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-aiff-stock-surge-pre-market-today/cZ3rwPpRIjD">Why Did AIFF Stock Surge Over 20% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Lunai Bioworks logo is seen displayed on a smartphone screen

Why Did LNAI Stock Surge Over 25% Today? 

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

Equity

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS...

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model Lunai Bioworks (NASDAQ: LNAI...

Best Manufacturing Stocks To Watch Today - March 17th

Taiwan Semiconductor Manufacturing, Applied Materials, and Lunai Bioworks are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

<ul class="summary-bullets"><li>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.</li><li>The company said in February that its newly issued patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.</li><li>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.</li></ul>Lunai Bioworks Inc. (LNAI) shares soared more than 200% in Tuesday’s opening trade before shedding some of the gains to hover about 150% higher to chalk a one-month high.While Lunai has&nbsp;not made&nbsp;any&nbsp;announcements recently nor has it made a fresh filing with the U.S. Securities and Exchange Commission (SEC), the stock could be drawing retail interest amid an increased interest in AI on the sidelines of Nvidia’s GTC event.Lunai announced in February that it has locked down its core AI architecture with the issuance of a fresh patent to enable precision disease subtyping.Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.<h2 class="st-heading-2">What Is The Patent About?</h2>Lunai said its patent covers a key first step in its platform that standardizes data and removes bias before AI modeling begins.Since AI drug discovery depends on data quality, the system is designed to detect and fix inconsistencies across genomic, clinical, imaging, and other datasets to improve reliability, the company said.By strengthening this core data layer, Lunai stated that it aims to better identify patient subtypes and link them to the gene networks driving specific diseases.“This patent protects the critical first step in our closed-loop AI architecture, increasing confidence in biomarker discovery, disease stratification, and gene network mapping across our CNS and biodefense programs,” said Lunai CEO David Weinstein.<h2 class="st-heading-2">Lunai Announces Sentinel</h2>In January, Lunai announced a new product named Sentinel, an AI safeguard that is designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents.The company said that Sentinel is a real-time biosecurity layer that screens molecular outputs before they are produced, stopping potentially hazardous designs at the source.<h2 class="st-heading-2">Lunai Announces Furloughs</h2>Lunai announced in March that it had furloughed some employees in the U.S. and Canada on February 27, noting that this was a temporary measure.The company also said that its CEO and CFO have agreed to temporarily defer the payment of their salaries during this period. It noted that this measure will be in place until it is able to secure additional capital.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/LNAI">Lunai Bioworks</a> trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.Meanwhile, Koyfin data shows that the short interest in Lunai Bioworks is at 3.3%, up from 1.5% last week.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260317_101902624_png_c94660d562.webp" alt="LNAI stock short interest as on March 17, 2026" width="2400" height="1240"><figcaption>LNAI stock short interest as on March 17, 2026 | Koyfin</figcaption></figure>The company announced in February that it had received a delisting notice from the Nasdaq, while adding that the exchange had granted a request for a hearing, which has been scheduled for March 26, 2026. As a result, the delisting action has been stayed pending a final decision by the exchange.<a href="https://stocktwits.com/symbol/LNAI">LNAI stock</a> is down 42% year-to-date and 93% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF Shares (VTI) and the Vanguard Extended Market Index Fund ETF Shares (VXF) are up 18% in this period.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-nvidia-partnership-quells-wall-street-concerns-for-ride-hailing-giant/cZ3EJfXRIX0">Uber's Nvidia Partnership For Autonomous Vehicles Quells Wall Street's Concerns For Ride-Hailing Giant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is This Micro-Cap Biotech Stock Up 150% Today?

Despite the LNAI stock soaring on Tuesday, the company’s shares are still down more than 93% from the stock’s 52-week high of $7.7.

Why Is LNAI Stock Skyrocketing Today?

Top Biotech Stocks To Follow Today - March 17th

Vertex Pharmaceuticals, bioAffinity Technologies, Lunai Bioworks, Danaher, Moderna, ImmunityBio, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...

Small Caps Surge on Breakouts, Biotech Validation, and “Real-World” Tech Adoption

Momentum is building across small-cap names this week, with a mix of technical breakouts, clinical validation, and commercialization milestones driving a more constructive tone beneath the surface of the market. $LNAI, $BIAF, $IBRX, $KBLB, $UCAR, $LIDR, $JTAI, $FLYX

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent...

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Lunai Bioworks Inc.

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

LNAI
Lunai Bioworks Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LNAI News

LNAILunai Bioworks Inc.